Press Detail

PRESS RELEASE

Biotest increases EBIT significantly

- Strong EBIT increase to EUR 18.2 million vs. EUR 2.3 million

- Increase of revenue by 6.4% to EUR 306 million

- Operating Cash flow increased to EUR 50 million

Dreieich, 11 August 2016. In the first half of 2016 the Biotest Group recorded revenue of EUR 306.1 million, representing an increase of 6.4% compared to the same period of the previous year (EUR 287.7 million). The markets of North America as well as Middle East and Africa made the most significant contribution to the revenue growth. However, the company achieved the highest growth rates year-on-year in the Central and South America region.

Despite higher expenses for the development of new products and the expansion of the production facility within the "Biotest Next Level" project in the amount of EUR 17 million, the EBIT increased considerably from EUR 2.3 million to EUR 18.2 million. A higher gross profit, a better utilization of the US facility and significantly reduced expenses for the monoclonal antibodies were the main drivers for the EBIT increase. The operating cash flow increased by 59.0% to EUR 49.6 million vs. EUR 31.2 million in the previous year period.

This resulted in earnings before taxes (EBT) of EUR 13.9 million for the Biotest Group compared to EUR 2.1 million in the same period of the previous year. Earnings after taxes (EAT) amounted to EUR 7.7 million (same period of the previous year: EUR -2.2 million). Earnings per share thus increased from EUR -0.05 to EUR +0.19 in the period under review.

Outlook:
The Board of Management confirms the guidance of an increase in sales in the low single-digit percentage range and an EBIT in the range of EUR 33 to 35 million for 2016.

The half-year report can be downloaded from Biotest's website: http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.